Skip to main content
Profile picture for Aurelie Najm, MD, PhD

Aurelie Najm, MD, PhD

Dr AurĂ©lie Najm is a Senior Clinical Fellow in Immunology in the Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, UK and an honorary consultant Rheumatologist. Her areas of interest include synovial tissue biology, epigenetics of rheumatic diseases and digital health applications in clinical care and research (machine learning, AI). She is the co-chair of the EULAR Synovitis Study Group. Follow her on Twitter: @AurelieRheumo.

Articles By Aurelie Najm, MD, PhD

Feet, foot

Pre-clinical RA: starting off the wrong foot

Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.

Read Article
SI AS SpA ACR

TNF inhibitors and radiographic progression in axSpA

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article
SI AS SpA ACR

TNF inhibitors and radiographic progression in axSpA

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article
Feet, foot

Pre-clinical RA: starting off the wrong foot

Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.

Read Article
joint.wrist_.pain_.CTS_.Carpal.jpg

RA after 70: Too Old for bioDMARDs?

In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.

Read Article
lung%2Cbright.jpg

New insights in RA-ILD therapeutics

RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed tomography (HRCT), which is the most sensitive for pre-clinical RA-ILD diagnosis. But why would we want to diagnose early a manifestation that we cannot treat?

Read Article
×